Recombinant Human Activated Protein C in Sepsis: Assessing Its Clinical Use

This publication has 19 references indexed in Scilit:

• Efficacy and Safety of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis
  JAMA, 2003
• Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*
  Critical Care Medicine, 2003
• Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials
  Critical Care Medicine, 2003
• Risk and the Efficacy of Antiinflammatory Agents
  American Journal of Respiratory and Critical Care Medicine, 2002
• Risks and Benefits of Activated Protein C Treatment for Severe Sepsis
  New England Journal of Medicine, 2002
• Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock
  JAMA, 2002
• Severe Sepsis — A New Treatment with Both Anticoagulant and Antiinflammatory Properties
  New England Journal of Medicine, 2001
• Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
  New England Journal of Medicine, 2001
• Stress doses of hydrocortisone reverse hyperdynamic septic shock
  Critical Care Medicine, 1999
• HYDROCORTISONE REVERSES REFRACTORY SEPTIC SHOCK
  Critical Care Medicine, 1999